Vincent Verschaeve

819 total citations
21 papers, 389 citations indexed

About

Vincent Verschaeve is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Genetics. According to data from OpenAlex, Vincent Verschaeve has authored 21 papers receiving a total of 389 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 7 papers in Molecular Biology and 6 papers in Genetics. Recurrent topics in Vincent Verschaeve's work include Glioma Diagnosis and Treatment (6 papers), Renal cell carcinoma treatment (4 papers) and Brain Metastases and Treatment (4 papers). Vincent Verschaeve is often cited by papers focused on Glioma Diagnosis and Treatment (6 papers), Renal cell carcinoma treatment (4 papers) and Brain Metastases and Treatment (4 papers). Vincent Verschaeve collaborates with scholars based in Belgium, United Kingdom and Australia. Vincent Verschaeve's co-authors include Brieuc Sautois, Sylvie Rottey, Jean‐Marie Vandenbulcke, Emmanuel Seront, Lionel D’Hondt, Jean‐Charles Goeminne, Didier Verhoeven, Stephanie Du Four, Bertrand Filleul and Johnny Duerinck and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Vincent Verschaeve

18 papers receiving 384 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vincent Verschaeve Belgium	9	157	147	112	100	94	21	389
Toshikazu Okaneya Japan	12	141 0.9×	152 1.0×	124 1.1×	25 0.3×	124 1.3×	51	423
Paule Augereau France	11	102 0.6×	133 0.9×	224 2.0×	46 0.5×	45 0.5×	45	402
Lydia Dreosti South Africa	10	157 1.0×	179 1.2×	300 2.7×	61 0.6×	33 0.4×	20	472
Frances Rae United Kingdom	8	194 1.2×	67 0.5×	64 0.6×	108 1.1×	147 1.6×	11	434
Pauline du Rusquec France	10	93 0.6×	160 1.1×	225 2.0×	31 0.3×	37 0.4×	25	400
Fazıl Aydin Türkiye	11	69 0.4×	88 0.6×	132 1.2×	27 0.3×	77 0.8×	32	345
Salma Alam United Kingdom	10	91 0.6×	160 1.1×	143 1.3×	28 0.3×	53 0.6×	14	332
Jinan Ma China	12	143 0.9×	101 0.7×	174 1.6×	19 0.2×	42 0.4×	43	397
Marcel Odaimi United States	10	68 0.4×	165 1.1×	137 1.2×	176 1.8×	36 0.4×	33	391
C. Cruickshank United Kingdom	6	106 0.7×	123 0.8×	129 1.2×	20 0.2×	113 1.2×	11	370

Countries citing papers authored by Vincent Verschaeve

Since Specialization

Citations

This map shows the geographic impact of Vincent Verschaeve's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vincent Verschaeve with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vincent Verschaeve more than expected).

Fields of papers citing papers by Vincent Verschaeve

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vincent Verschaeve. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vincent Verschaeve. The network helps show where Vincent Verschaeve may publish in the future.

Co-authorship network of co-authors of Vincent Verschaeve

This figure shows the co-authorship network connecting the top 25 collaborators of Vincent Verschaeve. A scholar is included among the top collaborators of Vincent Verschaeve based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vincent Verschaeve. Vincent Verschaeve is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kenis, Cindy, Koen Milisen, Philip R. Debruyne, et al.. (2022). Functional status in older patients with cancer and a frailty risk profile: A multicenter observational study. Journal of Geriatric Oncology. 13(8). 1162–1171. 8 indexed citations

Kenis, Cindy, Lore Decoster, Johan Flamaing, et al.. (2022). Incidence of falls and fall-related injuries and their predictive factors in frail older persons with cancer: a multicenter study. BMC Geriatrics. 22(1). 877–877. 20 indexed citations

Rasschaert, Marika, Christof Vulsteke, Vincent Verschaeve, et al.. (2020). AMTRA: a multicentered experience of a web-based monitoring and tailored toxicity management system for cancer patients. Supportive Care in Cancer. 29(2). 859–867. 16 indexed citations

Vanmechelen, Maxime, Diether Lambrechts, Thomas Van Brussel, et al.. (2018). Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib. Clinical Genitourinary Cancer. 17(2). e235–e246. 4 indexed citations

Decoster, Lore, Chantal Quinten, Cindy Kenis, et al.. (2018). Quality of life (QoL) in older patients (pts) with cancer and prognostic factors for QoL decline.. Journal of Clinical Oncology. 36(15_suppl). 10010–10010. 2 indexed citations

Lambrechts, Diether, Annelies Verbiest, Thomas Van Brussel, et al.. (2018). ABCG2 Polymorphism rs2231142 and hypothyroidism in metastatic renal cell carcinoma patients treated with sunitinib. Acta Clinica Belgica. 74(3). 180–188. 4 indexed citations

Duerinck, Johnny, Stephanie Du Four, Frank Bouttens, et al.. (2017). Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma. Journal of Neuro-Oncology. 136(1). 115–125. 52 indexed citations

Decoster, Lore, Cindy Kenis, Johan Flamaing, et al.. (2017). Adherence to geriatric assessment (GA)-based recommendations in older patients (pts) with cancer.. Journal of Clinical Oncology. 35(15_suppl). 10010–10010. 1 indexed citations

Duerinck, Johnny, Stephanie Du Four, Fenne Vandervorst, et al.. (2016). Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma. Journal of Neuro-Oncology. 128(1). 147–155. 41 indexed citations

10.

Duerinck, Johnny, Stephanie Du Four, Frank Bouttens, et al.. (2016). Randomized phase II study of axitinib alone or combined with lomustine in patients with recurrent glioblastoma.. Journal of Clinical Oncology. 34(15_suppl). 2038–2038.

11.

Seront, Emmanuel, Sylvie Rottey, Bertrand Filleul, et al.. (2016). Phase II study of dual phosphoinositol‐3‐kinase ( PI 3K) and mammalian target of rapamycin ( mTOR ) inhibitor BEZ 235 in patients with locally advanced or metastatic transitional cell carcinoma. British Journal of Urology. 118(3). 408–415. 52 indexed citations

12.

Duerinck, Johnny, Paul M. Clément, Frank Bouttens, et al.. (2015). Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma. Journal of Neurology. 262(3). 742–751. 11 indexed citations

13.

Seront, Emmanuel, Sylvie Rottey, Bertrand Filleul, et al.. (2015). Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma (TCC).. Journal of Clinical Oncology. 33(15_suppl). e15535–e15535. 4 indexed citations

14.

Neyns, Bart, Johnny Duerinck, Stephanie Du Four, et al.. (2014). Randomized phase II study of axitinib versus standard of care in patients with recurrent glioblastoma.. Journal of Clinical Oncology. 32(15_suppl). 2018–2018. 3 indexed citations

15.

Duerinck, Johnny, Stephanie Du Four, Frank Bouttens, et al.. (2014). O10.07 * RANDOMIZED PHASE II STUDY OF AXITINIB VS. STANDARD OF CARE IN PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro-Oncology. 16(suppl 2). ii24–ii25. 1 indexed citations

16.

Seront, Emmanuel, Sylvie Rottey, Brieuc Sautois, et al.. (2012). Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Annals of Oncology. 23(10). 2663–2670. 102 indexed citations

17.

Boterberg, Tom, Paul M. Clément, E. Joosens, et al.. (2011). 8744 POSTER Extended Use of Adjuvant TMZ in Newly Diagnosed GBM Patients is Safe – Results From the Safety Analysis of the PATSGO Trial. European Journal of Cancer. 47. S587–S587. 1 indexed citations

18.

Verschaeve, Vincent, Lionel D’Hondt, Luc Verbeke, et al.. (2011). CeCil: A randomized, noncomparative phase II clinical trial of the effect of radiation therapy (RT) plus temozolomide (TMZ) combined with cilengitide or cetuximab on the 1-year overall survival of patients with newly diagnosed MGMT-promoter unmethylated glioblastoma.. Journal of Clinical Oncology. 29(15_suppl). TPS134–TPS134. 3 indexed citations

19.

Machiels, Jean‐Pascal, F Mazzeo, Bertrand Filleul, et al.. (2008). Prospective Randomized Study Comparing Docetaxel, Estramustine, and Prednisone With Docetaxel and Prednisone in Metastatic Hormone-Refractory Prostate Cancer. Journal of Clinical Oncology. 26(32). 5261–5268. 62 indexed citations

20.

Verschaeve, Vincent, et al.. (1997). Néphrotoxicité du cisplatine : Quelle prévention en pratique ?. Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)).

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact